Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome (Q37954521)

25 August 2017

title

Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome (English)

1 reference

25 August 2017

1 reference

M Camilleri

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

9 November 2011

1 reference

Clinical Pharmacology & Therapeutics

25 August 2017

published in

1 reference

25 August 2017

volume

91

1 reference

25 August 2017

issue

1

1 reference

25 August 2017

page(s)

44-59

1 reference

Systematic review: the effects of fibre in the management of chronic idiopathic constipation

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

AGA technical review on irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Developing irritable bowel syndrome guidelines through meta-analyses: does the emperor really have new clothes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Molecular, pharmacological and functional diversity of 5-HT receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Drugs acting on serotonin receptors for the treatment of functional GI disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Safety and tolerability of tegaserod in patients with chronic constipation: pooled data from two phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

5-HT4 receptor agonists: similar but not the same

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Association of TCF7L2 allelic variations with gastric function, satiation, and GLP-1 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Tegaserod-induced myocardial infarction: case report and hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Behavioural and new pharmacological treatments for constipation: getting the balance right

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

A placebo-controlled trial of prucalopride for severe chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effects of lubiprostone on human uterine smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Structure and function of the heat-stable enterotoxin receptor/guanylyl cyclase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

NHERF family and NHE3 regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Pilot study on the effect of linaclotide in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Efficacy of linaclotide for patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

The continuing importance of bile acids in liver and intestinal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Bile acid stimulation of colonic adenylate cyclase and secretion in the rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of glycine-conjugated bile acids with and without lecithin on water and glucose absorption in perfused human jejunum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Bile acids and colonic motility in the rabbit and the human

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

The proximal colonic motor response to rectal mechanical and chemical stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Chenodeoxycholate in Females With Irritable Bowel Syndrome-Constipation: A Pharmacodynamic and Pharmacogenetic Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Treatment of constipation with chenodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Inhibition of bergaptene toxicity by UV-A filters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

21 January 2018

Points of view: arrows

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of change of fecal bile acid excretion achieved by operative procedures on 1,2-dimethylhydrazine-induced colon cancer in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Bile acids: short and long term effects in the intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Opioid-induced constipation: challenges and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Oral naloxone reverses opioid-associated constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Methylnaltrexone for opioid-induced constipation in advanced illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Long-Term Safety and Efficacy of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules, a Novel Formulation Containing Morphine and Sequestered Naltrexone, in Patients with Chronic, Moderate to Severe Pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Update on abuse-resistant and abuse-deterrent approaches to opioid formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled pha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Parachlorophenylalanine Reversal of Tranylcypromine Effects in Depressed Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Conscientiousness and externalizing psychopathology: overlap, developmental patterns, and etiology of two related constructs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

In vitro characterization of viral fitness of therapy-resistant hepatitis B variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Pharmacological profile of ramosetron, a novel therapeutic agent for IBS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of meal ingestion on ileocolonic and colonic transit in health and irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

NK1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Substance P via NK1 receptor facilitates hyperactive bladder afferent signaling via action of ROS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Tachykinin receptors in the gut: physiological and pathological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Tachykinins in the gut. Part I. Expression, release and motor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

The troubled story of tachykinins and neurokinins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Neurokinin-1 receptor antagonists in the prevention of postoperative nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Dual and selective antagonism of neurokinin NK(1) and NK(2) receptor-mediated responses in human colon mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Corticotropin-releasing hormone and mast cells in the regulation of mucosal barrier function in the human colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Corticotropin-releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of alpha-helical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Neuroimaging placebo effects: new tools generate new questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Dose-response effect of a beta3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Risk of venous thromboembolism in hospitalized patients with peripherally inserted central catheters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Management of diarrhoeic type of irritable bowel syndrome with exclusion diet and disodium cromoglycate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

The Role of N-Methyl-d-Aspartate (NMDA) Receptors in Pain: A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Dextromethorphan: a review of N-methyl-d-aspartate receptor antagonist in the management of pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effects of the N-methyl-D-aspartate receptor on temporal summation of second pain (wind-up) in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Visualization of the domain structure of an L-type Ca2+ channel using electron cryo-microscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Pregabalin pharmacology and its relevance to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Identification of subunits of voltage-gated calcium channels and actions of pregabalin on intrinsic primary afferent neurons in the guinea-pig ileum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Pregabalin decreases visceral pain and prevents spinal neuronal activation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effects of pregabalin on visceral pain responses and colonic compliance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effect of the α2δ ligand, pregabalin, on colonic sensory and motor functions in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Emerging Pharmacologic Therapies for Irritable Bowel Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Mechanisms in IBS: something old, something new, something borrowed...

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Review article: new receptor targets for medical therapy in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

Effective Lipid Modification by Partial Ileal Bypass Reduced Long-term Coronary Heart Disease Mortality and Morbidity: Five-Year Posttrial Follow-up Report From the POSCH

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

The influence of cisapride on gastric tone and the perception of gastric distension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Peripheral 5-HT4 receptors.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Human isolated coronary artery contraction to sumatriptan characterised by the selective 5-HT1B/1D receptor antagonist GR55562

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

A multicenter analysis of axial femorotibial rotation after total knee arthroplasty

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Oral naloxone antagonizes loperamide-induced delay of orocecal transit

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Esophageal polypoid mass in a 78-year-old woman

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Serotonin now: clinical implications of inhibiting its synthesis with para-chlorophenylalanine

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Social behavior of monkeys selectively depleted of monoamines

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Proximal colonic response and gastrointestinal transit after high and low fat meals

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Role of neurokinin 3 receptors on responses to colorectal distention in the rat: electrophysiological and behavioral studies

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Potent NK1 antagonism by SR-140333 reduces rat colonic secretory response to immunocyte activation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Contribution of NK(2) tachykinin receptors to propulsion in the rabbit distal colon

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.261

7 January 2021

Identifiers

DOI

10.1038/CLPT.2011.261

1 reference

Dimensions Publication ID

25 August 2017

1036763946

0 references

1 reference